Logo image of EBS

EMERGENT BIOSOLUTIONS INC (EBS) Stock Fundamental Analysis

NYSE:EBS - New York Stock Exchange, Inc. - US29089Q1058 - Common Stock - Currency: USD

7.71  -0.13 (-1.66%)

After market: 7.92 +0.21 (+2.72%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to EBS. EBS was compared to 571 industry peers in the Biotechnology industry. Both the profitability and financial health of EBS have multiple concerns. EBS has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year EBS has reported negative net income.
EBS had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: EBS reported negative net income in multiple years.
In multiple years EBS reported negative operating cash flow during the last 5 years.
EBS Yearly Net Income VS EBIT VS OCF VS FCFEBS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M -400M -600M

1.2 Ratios

EBS has a Return On Assets of -14.13%. This is amongst the best in the industry. EBS outperforms 84.72% of its industry peers.
The Return On Equity of EBS (-41.07%) is better than 71.40% of its industry peers.
Industry RankSector Rank
ROA -14.13%
ROE -41.07%
ROIC N/A
ROA(3y)-13.66%
ROA(5y)-5.61%
ROE(3y)-39.61%
ROE(5y)-18.54%
ROIC(3y)N/A
ROIC(5y)N/A
EBS Yearly ROA, ROE, ROICEBS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of EBS (33.51%) is better than 75.31% of its industry peers.
EBS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EBS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.37%
GM growth 5Y-11.03%
EBS Yearly Profit, Operating, Gross MarginsEBS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

More info and screens

3

2. Health

2.1 Basic Checks

EBS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EBS has been increased compared to 1 year ago.
Compared to 5 years ago, EBS has more shares outstanding
EBS has a worse debt/assets ratio than last year.
EBS Yearly Shares OutstandingEBS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
EBS Yearly Total Debt VS Total AssetsEBS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of 0.94, we must say that EBS is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 0.94, EBS is doing good in the industry, outperforming 66.43% of the companies in the same industry.
The Debt to FCF ratio of EBS is 4.80, which is a neutral value as it means it would take EBS, 4.80 years of fcf income to pay off all of its debts.
EBS's Debt to FCF ratio of 4.80 is amongst the best of the industry. EBS outperforms 93.78% of its industry peers.
EBS has a Debt/Equity ratio of 1.30. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.30, EBS is not doing good in the industry: 81.35% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.3
Debt/FCF 4.8
Altman-Z 0.94
ROIC/WACCN/A
WACC7.8%
EBS Yearly LT Debt VS Equity VS FCFEBS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 2.88 indicates that EBS has no problem at all paying its short term obligations.
With a Current ratio value of 2.88, EBS is not doing good in the industry: 67.32% of the companies in the same industry are doing better.
A Quick Ratio of 1.47 indicates that EBS should not have too much problems paying its short term obligations.
EBS has a worse Quick ratio (1.47) than 81.53% of its industry peers.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 1.47
EBS Yearly Current Assets VS Current LiabilitesEBS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 77.49% over the past year.
The Revenue for EBS has decreased by -11.27% in the past year. This is quite bad
Measured over the past years, EBS shows a small growth in Revenue. The Revenue has been growing by 6.05% on average per year.
EPS 1Y (TTM)77.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%385.42%
Revenue 1Y (TTM)-11.27%
Revenue growth 3Y-12.3%
Revenue growth 5Y6.05%
Sales Q2Q%8.61%

3.2 Future

EBS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.79% yearly.
Based on estimates for the next years, EBS will show a small growth in Revenue. The Revenue will grow by 6.20% on average per year.
EPS Next Y84.98%
EPS Next 2Y54.32%
EPS Next 3Y31.62%
EPS Next 5Y14.79%
Revenue Next Year3.43%
Revenue Next 2Y2.93%
Revenue Next 3Y-2.51%
Revenue Next 5Y6.2%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
EBS Yearly Revenue VS EstimatesEBS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
EBS Yearly EPS VS EstimatesEBS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4 6

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

EBS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 3.69, the valuation of EBS can be described as very cheap.
Based on the Price/Forward Earnings ratio, EBS is valued cheaply inside the industry as 98.76% of the companies are valued more expensively.
EBS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.70.
Industry RankSector Rank
PE N/A
Fwd PE 3.69
EBS Price Earnings VS Forward Price EarningsEBS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

99.82% of the companies in the same industry are more expensive than EBS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 3.02
EV/EBITDA N/A
EBS Per share dataEBS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

EBS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
EBS's earnings are expected to grow with 31.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y54.32%
EPS Next 3Y31.62%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EBS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EMERGENT BIOSOLUTIONS INC

NYSE:EBS (2/21/2025, 8:14:56 PM)

After market: 7.92 +0.21 (+2.72%)

7.71

-0.13 (-1.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-03 2025-03-03/amc
Inst Owners64.96%
Inst Owner Change-90.87%
Ins Owners1.08%
Ins Owner Change-0.4%
Market Cap417.73M
Analysts74.29
Price Target13.77 (78.6%)
Short Float %13.05%
Short Ratio6.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)362.91%
Min EPS beat(2)-143.07%
Max EPS beat(2)868.88%
EPS beat(4)2
Avg EPS beat(4)148.12%
Min EPS beat(4)-301.25%
Max EPS beat(4)868.88%
EPS beat(8)2
Avg EPS beat(8)-73.33%
EPS beat(12)4
Avg EPS beat(12)-233.81%
EPS beat(16)6
Avg EPS beat(16)-184.42%
Revenue beat(2)1
Avg Revenue beat(2)15.25%
Min Revenue beat(2)-2.22%
Max Revenue beat(2)32.73%
Revenue beat(4)2
Avg Revenue beat(4)14.71%
Min Revenue beat(4)-6.7%
Max Revenue beat(4)35.04%
Revenue beat(8)6
Avg Revenue beat(8)18.86%
Revenue beat(12)8
Avg Revenue beat(12)11.59%
Revenue beat(16)9
Avg Revenue beat(16)6.36%
PT rev (1m)12.5%
PT rev (3m)12.5%
EPS NQ rev (1m)22.66%
EPS NQ rev (3m)22.66%
EPS NY rev (1m)18.5%
EPS NY rev (3m)29.13%
Revenue NQ rev (1m)-1.67%
Revenue NQ rev (3m)-1.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.69
P/S 0.37
P/FCF 3.02
P/OCF 2.45
P/B 0.82
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)2.09
Fwd EY27.12%
FCF(TTM)2.55
FCFY33.06%
OCF(TTM)3.15
OCFY40.86%
SpS20.77
BVpS9.38
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.13%
ROE -41.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.51%
FCFM 12.27%
ROA(3y)-13.66%
ROA(5y)-5.61%
ROE(3y)-39.61%
ROE(5y)-18.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.37%
GM growth 5Y-11.03%
F-Score6
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 1.3
Debt/FCF 4.8
Debt/EBITDA N/A
Cap/Depr 29%
Cap/Sales 2.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.88
Quick Ratio 1.47
Altman-Z 0.94
F-Score6
WACC7.8%
ROIC/WACCN/A
Cap/Depr(3y)159.63%
Cap/Depr(5y)139.66%
Cap/Sales(3y)16.79%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%385.42%
EPS Next Y84.98%
EPS Next 2Y54.32%
EPS Next 3Y31.62%
EPS Next 5Y14.79%
Revenue 1Y (TTM)-11.27%
Revenue growth 3Y-12.3%
Revenue growth 5Y6.05%
Sales Q2Q%8.61%
Revenue Next Year3.43%
Revenue Next 2Y2.93%
Revenue Next 3Y-2.51%
Revenue Next 5Y6.2%
EBIT growth 1Y68.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year127.06%
EBIT Next 3Y29.96%
EBIT Next 5Y16.99%
FCF growth 1Y176.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.54%
OCF growth 3YN/A
OCF growth 5YN/A